Conaz 150 mg (Capsule)
Medicine Details
| Category | Details |
|---|---|
| Generic | Fluconazole |
| Company | Orion pharma ltd |
| Also available as |
Indications
- Vaginal Candidiasis
- Oropharyngeal Candidiasis
- Oesophageal Candidiasis
- Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea
- Kerion
- Pityriasis versicolor
- Onychomycosis
- Invasive candidal infections and cryptococcal infections (including meningitis)
- Prevention of cryptococcal meningitis
- Prevention of fungal infections in immunocompromised patients
- Systemic Candidiasis and Cryptococcal infection
- Superficial Candidiasis
- Fungal urinary tract infections
- Disseminated candidiasis
- Prophylaxis for fungal infection in neutropenic cancer patients
- Acute treatment of other systemic fungal infections such as coccidioidomycosis and histoplasmosis
Pharmacology
Triazole antifungal agent. Potent inhibitor of fungal cytochrome P-450 dependent enzymes. Essential component of fungal cell membrane responsible for the synthesis of ergosterol.
Dosage & Administration
- Adults:
- Vaginal Candidiasis: 150 mg as a single dose
- Oropharyngeal Candidiasis: 200 mg in 1st day followed by 100 mg daily for 14 days
- Oesophageal Candidiasis: 200 mg in 1st day followed by 100 mg daily for 14-30 days
- Tinea corporis/Tinea cruris/Tinea pedis/Other Tinea: 150 mg weekly for 4-6 weeks
- Kerion: 50 mg daily for 20 days
- Pityriasis versicolor: 400 mg as a single dose
- Onychomycosis: 150 mg weekly for 12 months
- Invasive candidal infections and cryptococcal infections (including meningitis): Orally or by IV infusion, 400 mg on first day then 200-400 mg daily
- Prevention of cryptococcal meningitis: Orally or by IV infusion 200 mg daily
- Prevention of fungal infections in immunocompromised patients: Orally or by IV infusion, 50-400 mg daily
- Child over 1 year:
- In Superficial Candidiasis: 1-2 mg/kg daily
- In Systemic Candidiasis & Cryptococcal infection: 3-6 mg/kg daily
- Use in Specific Population:
- Elderly patient: Normal dose should be used if there is no evidence of renal impairment
- Renal Impairment: No adjustment in single dose therapy is required. In multiple dose therapy of patients with renal impairment, normal doses should be given on days 1 and 2 of treatment and then the dosage intervals should be modified based on creatinine clearance
Interaction
- Increased prothombin time after warfarin administration
- Prolonged serum half-life of concomitantly administered oral sulphonyl ureas
- Increased plasma concentrations of fuconazole by 40% with co-administration of multiple-dose hydrochlorothiazide
- Potential increase in the level of phenytoin when co-administered with fuconazole
- 25% decrease in the AUC and 20% shorter half-life of fuconazole when co-administered with rifampicin
- Kinetic studies with combined oral contraceptive
- Slow increase in cyclosporin concentrations
- No clinically significant impairment of fuconazole absorption when co-administered with certain factors
- 18% decrease in mean plasma clearance of theophylineafter administration of fuconazole 200mg for 14 days
Contraindications
Fluconazole should not be used in patients with known hypersensitivity to Fluconazole or related triazole compounds
Side Effects
Common side effects include symptoms associated with the gastrointestinal tract, nausea, abdominal discomfort, diarrhea, and flatulence. Other adverse events such as rash are rarely encountered (Incidence less than 1%). Anaphylaxis has been reported in rare cases
Pregnancy & Lactation
Adverse fetal effects seen in animals only at dose levels associated with maternal toxicity. Use in pregnancy or in women of child bearing potential unless adequate contraception is employed is not recommended
Precautions & Warnings
- Abnormalities of hepatic, renal, hematological, and other biochemical function tests: Observed in some patients, particularly those with serious underlying diseases such as AIDS and cancer
- Hepatic necrosis: Rare post-mortem findings in patients receiving multiple dose fuconazole and concomitant medications, potentially hepatotoxic
- Exfoliative cutaneous reactions: Rarely observed, particularly in AIDS patients
Use in Special Populations
- Use in the elderly: Normal dose recommended if no evidence of renal impairment
- Use in renal impairment: No adjustments in single dose therapy required; in multiple dose therapy, dosage should be given based on creatinine clearance
Overdose Effects
Supportive measures and symptomatic treatment recommended; forced volume diuresis may help increase elimination rate; haemodialysis can decrease plasma levels by approximately 50%
Therapeutic Class
Drugs for subcutaneous and mycoses
Storage Conditions
Keep in a dry place away from light and heat. Keep out of the reach of children.